OHSU researchers show that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PARPi resistance
Quigley D, Alumkal J, Wyatt A, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas GV, Tomlins S, Knudsen K, Lord C, Ryan C, Youngren J, Beer T, Ashworth A, Small E, Feng F. Analysis of circulating cell-free DNA identifies multi-clonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discovery. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.
Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitor